Literature DB >> 25266109

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Maria J Perugorria1, Tatyana V Masyuk2, Jose J Marin3, Marco Marzioni4, Luis Bujanda1, Nicholas F LaRusso2, Jesus M Banales1.   

Abstract

Polycystic liver diseases are genetic disorders characterized by progressive bile duct dilatation and/or cyst development. The large volume of hepatic cysts causes different symptoms and complications such as abdominal distension, local pressure with back pain, hypertension, gastro-oesophageal reflux and dyspnea as well as bleeding, infection and rupture of the cysts. Current therapeutic strategies are based on surgical procedures and pharmacological management, which partially prevent or ameliorate the disease. However, as these treatments only show short-term and/or modest beneficial effects, liver transplantation is the only definitive therapy. Therefore, interest in understanding the molecular mechanisms involved in disease pathogenesis is increasing so that new targets for therapy can be identified. In this Review, the genetic mechanisms underlying polycystic liver diseases and the most relevant molecular pathways of hepatic cystogenesis are discussed. Moreover, the main clinical and preclinical studies are highlighted and future directions in basic as well as clinical research are indicated.

Entities:  

Mesh:

Year:  2014        PMID: 25266109      PMCID: PMC4526263          DOI: 10.1038/nrgastro.2014.155

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  121 in total

Review 1.  Polycystic liver diseases: congenital disorders of cholangiocyte signaling.

Authors:  Mario Strazzabosco; Stefan Somlo
Journal:  Gastroenterology       Date:  2011-04-22       Impact factor: 22.682

2.  Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.

Authors:  Luca Fabris; Massimiliano Cadamuro; Romina Fiorotto; Tania Roskams; Carlo Spirlì; Saida Melero; Aurelio Sonzogni; Ruth E Joplin; Lajos Okolicsanyi; Mario Strazzabosco
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

Review 3.  Systematic review: the pathophysiology and management of polycystic liver disease.

Authors:  F Temmerman; L Missiaen; B Bammens; W Laleman; D Cassiman; C Verslype; J van Pelt; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2011-07-26       Impact factor: 8.171

4.  Liver development in the rat and in man during the embryonic period (Carnegie stages 11-23).

Authors:  G Godlewski; R Gaubert-Cristol; S Rouy; M Prudhomme
Journal:  Microsc Res Tech       Date:  1997-11-15       Impact factor: 2.769

5.  PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors:  Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-08

6.  Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease.

Authors:  Joost P H Drenth; Rene H M te Morsche; Renate Smink; Juan S Bonifacino; Jan B M J Jansen
Journal:  Nat Genet       Date:  2003-02-10       Impact factor: 38.330

7.  ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.

Authors:  Carlo Spirli; Stefano Okolicsanyi; Romina Fiorotto; Luca Fabris; Massimiliano Cadamuro; Silvia Lecchi; Xin Tian; Stefan Somlo; Mario Strazzabosco
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

8.  Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate.

Authors:  Thomas Decaens; Cécile Godard; Aurélien de Reyniès; David S Rickman; François Tronche; Jean-Pierre Couty; Christine Perret; Sabine Colnot
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

Review 10.  Polycystin-1: a master regulator of intersecting cystic pathways.

Authors:  Sorin V Fedeles; Anna-Rachel Gallagher; Stefan Somlo
Journal:  Trends Mol Med       Date:  2014-01-31       Impact factor: 11.951

View more
  36 in total

1.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

Review 2.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 3.  Pathology of Fibropolycystic Liver Diseases.

Authors:  Jason Lewis
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

4.  Genetics: Novel causative genes for polycystic liver disease.

Authors:  María J Perugorria; Jesús M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-31       Impact factor: 46.802

5.  Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis.

Authors:  Tassos Grammatikopoulos; Melissa Sambrotta; Sandra Strautnieks; Pierre Foskett; A S Knisely; Bart Wagner; Maesha Deheragoda; Chris Starling; Giorgina Mieli-Vergani; Joshua Smith; Laura Bull; Richard J Thompson
Journal:  J Hepatol       Date:  2016-07-25       Impact factor: 25.083

6.  Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.

Authors:  Maria Lorenzo Pisarello; Tatyana V Masyuk; Sergio A Gradilone; Anatoliy I Masyuk; Jingyi F Ding; Pui-Yuen Lee; Nicholas F LaRusso
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

Review 7.  Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma.

Authors:  Sergio A Gradilone; Maria J Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Maria Lorenzo Pisarello; Brynn N Howard; Bing Q Huang; Pui-Yuen Lee; Xavier Fung; Eduard Sergienko; Robert J Ardecky; Thomas D Y Chung; Anthony B Pinkerton; Nicholas F LaRusso
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

9.  Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

Review 10.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.